Startseite>>Signaling Pathways>> Ox Stress Reagents>> Pro-Oxidant Activity>>SRS11-92

SRS11-92 (Synonyms: AA9)

Katalog-Nr.GC40922

SRS11-92, ein Ferrostatin-1 (Fer-1)-Analogon, ist ein potenter Ferroptose-Hemmer.

Products are for research use only. Not for human use. We do not sell to patients.

SRS11-92 Chemische Struktur

Cas No.: 1467047-25-1

Größe Preis Lagerbestand Menge
1mg
23,00 $
Auf Lager
5mg
102,00 $
Auf Lager
10mg
173,00 $
Auf Lager
25mg
357,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SRS11-92 is a ferroptosis inhibitor and a derivative of ferrostatin-1 . It inhibits ferroptotic cell death induced by erastin in HT-1080 human fibrosarcoma cells (EC50 = 6 nM). SRS11-92 (2 µM) inhibits iron-induced cell death in isolated mouse kidney proximal tubules, and fully protects rat oligodendrocytes from cystine deprivation-induced cell death in an in vitro model of periventricular leukomalacia when used at a concentration of 100 nM. It also increases survival of medium spiny neurons in rat corticostriatal brain slices in an in vitro model of Huntington's disease in a concentration-dependent manner. SRS11-92 (3 µM) increases production of reactive oxygen species (ROS) in L. major promastigotes in a time-dependent manner. It is selectively toxic to L. major promastigotes (LD50 = 3.34 µM) over U2OS human osteoblasts, RAW 264.7 macrophages, and intraperitoneal macrophages when used at a concentration of 80 µM.

Bewertungen

Review for SRS11-92

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SRS11-92

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.